Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Stopped early · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Hypertrophic Cardiomyopathy

In brief

The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with symptomatic hypertrophic cardiomyopathy (HCM).

Key facts

Study ID
NCT02291237
Run by
Gilead Sciences
People needed
172
Starts
2015-02-05
Expected to finish
2017-02-17
Last updated by the study team
2018-09-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.